Main View
This view is used for searching all possible sources.
First Page Previous Page 1 2 3 4 5 6 7 8 9 10 Next Page Last Page
 
1
KINRIX� (Diphtheria and Tetanus Toxoids and Acellular Pertussis ...

... Product: Diphtheria and Tetanus Toxoids and Acellular Pertussis Adsorbed and Inactivated Poliovirus Vaccine; KINRIX FDA STN: 125260 ...

Center for Biologics Evaluation and Research (CBER)

2
Pentacel - Diphtheria and Tetanus Toxoids and Acellular Pertussis ...

... Haemophilus b Conjugate Vaccine (Tetanus Toxoid Conjugate) Reconstituted with Diphtheria and Tetanus Toxoids and Acellular Pertussis Vaccine Adsorbed Combined ...

Center for Biologics Evaluation and Research (CBER)

3
Tetanus Toxoid, Reduced Diphtheria Toxoid and Acellular Pertussis ...

... US. -. Tetanus Toxoid, Reduced Diphtheria Toxoid and Acellular Pertussis Vaccine, Adsorbed. -. Products. Adacel Sanofi Pasteur, Ltd. ...

Center for Biologics Evaluation and Research (CBER)

4
Diphtheria and Tetanus Toxoids and Acellular Pertussis Adsorbed ...

... Diphtheria and Tetanus Toxoids and Acellular Pertussis Adsorbed and Inactivated Poliovirus Vaccine. -. Product. Kinrix. -. Contact Us. Consumer Affairs Branch ( ...

Center for Biologics Evaluation and Research (CBER)

5
Real-time polymerase chain reaction detection of Bordetella pertussis DNA in acellular pertussis vaccines.
2008-01-01

Using 2 real-time polymerase chain reaction (PCR) assays for Bordetella pertussis, 2 of 5 acellular pertussis vaccines were found to contain B. pertussis DNA. Because residual DNA in vaccines can cause environmental contamination, the administration of ...

PubMed

6
Outbreaks of Respiratory Illness Mistakenly Attributed to Pertussis...
2010-06-17

members offered PEP and vaccination with the newly licensed tetanus toxoid, reduced diphtheria toxoid, acellular pertussis vaccine (Tdap) to all personnel in the hospital's...

Science.gov Websites

7
Workshop on Acellular Pertussis Vaccines Held at Bethesda, Maryland on September 22-24, 1986, Transcript.
1986-01-01

The document is the printed transcript of a workshop held to discuss the current status of research to develop and clinically test new acellular pertussis vaccines.

National Technical Information Service (NTIS)

8
Autistic Spectrum Disorder and Vaccines

Page 1. Post-Approval Adverse Event Review: Diphtheria and Tetanus Toxoids and Acellular Pertussis Adsorbed, Inactivated ...

Center for Biologics Evaluation and Research (CBER)

9
CDC - Pertussis: Publications
2011-08-07

and Licensures CDC. Updated Recommendations for the Use of Tetanus Toxoid, Reduced Diphtheria Toxoid and Acellular Pertussis (Tdap) Vaccine from the Advisory Committee on...

Science.gov Websites

10
Pentacel - Diphtheria and Tetanus Toxoids and Acellular Pertussis ...

... is manufactured at Aventis Pasteur Limited (Canada) and Haemophilus b Conjugate Vaccine (Tetanus Protein�Conjugate) Vaccine referred to as PRP�T Vaccine is ...

Center for Biologics Evaluation and Research (CBER)

11
Notice to Readers: Recommended Childhood Immunization Schedule...
2010-06-17

from the schedule, endorsed an all-inactivated poliovirus vaccine (IPV) schedule for polio vaccination, recommended exclusive use of acellular pertussis vaccines for all doses...

Science.gov Websites

12
Vaccines: VPD-VAC/Tetanus/In-Short
2011-08-07

Yes, the Advisory Committee on Immunization Practices (ACIP) recommends 5 doses of diphtheria and tetanus toxoids and acellular pertussis (DTaP) vaccine for infants and children....

Science.gov Websites

13
Autistic Spectrum Disorder and Vaccines

Page 1. Post-Approval Adverse Event Review: Diphtheria and Tetanus Toxoids and Acellular Pertussis Adsorbed and Inactivated Poliovirus Vaccine KINRIX� ...

Center for Biologics Evaluation and Research (CBER)

14
Your Child's Cough

... is given as part of the DTaP vaccine (diphtheria, tetanus, acellular pertussis). The Tdap vaccine (which is similar to DTaP but with lower concentrations of diphtheria and tetanus toxoid for adults) is given to ...

MedlinePLUS

15
Haemophilus b Conjugate Vaccine Tetanus Toxoid Conjugate (ActHIB)

... Diphtheria and Tetanus Toxoids and Acellular Pertussis Vaccine Adsorbed (DTaP; Tripedia®), and used according to the Indications and Usage section of the FDA ...

Center for Biologics Evaluation and Research (CBER)

16
Of mice and men: asymmetric interactions between Bordetella pathogen species

after introduction of acellular pertussis vaccines. Archives of Disease in Childhood 88, 684 the coexistence of the two pathogens, with or without vaccination. We then track the dynamics of the system following the introduction of anti-pertussis vaccination. Our results ...

E-print Network

17
Nonspecific Resistance Induced by an Immunopharmacologic Agent Derived from Bordetella pertussis.
1985-01-01

Treatment of mice with Bordetella pertussis vaccine resulted in resistance to mouse adenovirus infection. Antiviral activity was associated with surface components of B. pertussis. Acellular fractions with antiviral activity were obtained by relatively ge...

National Technical Information Service (NTIS)

18
Bordetella pertussis Infection or Vaccination Substantially Protects Mice against B. bronchiseptica

, vaccination with purified B. pertussis-derived pertactin, filamentous hemagglutinin or the human acellular- derived antigens in the acellular vaccine, Adacel, or the individual proteins pertactin or filamentous killed B. pertussis in 1 ml of PBS [33], 40 mg of purified ...

E-print Network

19
Synergic effect of genotype changes in pertussis toxin and pertactin on adaptation to an acellular pertussis vaccine in the murine intranasal challenge model.
2010-03-31

The Bordetella pertussis pertussis toxin and pertactin (Prn) are protective antigens and are contained in acellular pertussis vaccines. Polymorphisms in the A subunit of pertussis toxin (PtxA) and pertactin have been proposed to mediate vaccine ...

PubMed

20
Synergic Effect of Genotype Changes in Pertussis Toxin and Pertactin on Adaptation to an Acellular Pertussis Vaccine in the Murine Intranasal Challenge Model?
2010-05-31

The Bordetella pertussis pertussis toxin and pertactin (Prn) are protective antigens and are contained in acellular pertussis vaccines. Polymorphisms in the A subunit of pertussis toxin (PtxA) and pertactin have been proposed to mediate vaccine ...

PubMed Central

First Page Previous Page 1 2 3 4 5 6 7 8 9 10 Next Page Last Page
 
First Page Previous Page 1 2 3 4 5 6 7 8 9 10 Next Page Last Page
 
21
Pertussis Vaccination: Use of Acellular Pertussis Vaccines Among...
2010-06-17

toxoid and 5.0 Lf of tetanus toxoid. The combined components are adsorbed using aluminum potassium sulfate and preserved with 1:10,000 thimerosal (Table_1)....

Science.gov Websites

22
CDC Features - Pertussis (Whooping Cough) - What You Need To...
2011-08-06

Tdap and Td vaccines See Updated Recommendations for Use of Tetanus Toxoid, Reduced Diphtheria Toxoid and Acellular Pertussis (Tdap) Vaccine from the Advisory Committee on...

Science.gov Websites

23
CDC - HPV Vaccine Safety - Vaccine Safety
2011-08-07

visit this page: About CDC.gov. Vaccine Safety Vaccine Safety Vaccines Safety Basics Diphtheria, Tetanus, and Acellular Pertussis (DTaP) Haemophilus Influenzae Type B (Hib) Hib...

Science.gov Websites

24
Study of Swelling and Other Reactions to Evaluate Safety of ...

... Health officials recommend that children receive a fifth dose of the diphtheria- tetanus-acellular pertussis (DTaP) vaccines when they begin school. ...

Center for Biologics Evaluation and Research (CBER)

25
October 1, 2009 Approval Letter

... with Diptheria, Tetanus Toxoids, and Acellular Pertussis Vaccine, Absorbed (Infanrix®) and ... of HAVRIX® (720 EL.U/0.5 mL dose) with Infanrix and ...

Center for Biologics Evaluation and Research (CBER)

26
Margaret B. Rennels

... administered separately versus combined in younger and older ... Disease Among Infants and Young Children. ... Toxoid-tetanus toxoid acellular pertussis vaccine as a ...

Center for Biologics Evaluation and Research (CBER)

27
January 29, 1997 Approval Letter - Infanrix

... 1090, to import Diphtheria and Tetanus Toxoids and Acellular Pertussis Vaccine Adsorbed (DTaP), "Infanrix," for the primary and booster immunization of infants ...

Center for Biologics Evaluation and Research (CBER)

28
Diphtheria and Tetanus Toxoids and Acellular Pertussis Vaccine ...

... with mild illness such as diarrhea, mild upper respiratory infections with ... All major equipment and analytical methodology have been appropriately validated by ...

Center for Biologics Evaluation and Research (CBER)

29
Diphtheria and Tetanus Toxoids and Acellular Pertussis Adsorbed ...

... febrile seizures, brachial neuritis, arthritis, anaphylaxis, erythema ... other vaccines has not been studied with the ... ofpotential safety risks, a study shows that ...

Center for Biologics Evaluation and Research (CBER)

30
Diphtheria and Tetanus Toxoids and Acellular Pertussis ...

... post-vaccination � Adverse events that resulted in a hospital admission, life-threatening ... that represented a change in health status, daily, on Days 0 ...

Center for Biologics Evaluation and Research (CBER)

31
Childhood Vaccine Schedule

... failure. 1 to 4 Months HepB 2 Months Diphtheria, tetanus and acellular pertussis� DTaP Prevents: Diphtheria, a serious bacterial infection that can lead to ...

MedlinePLUS

32
APPENDIX A. Summary of Recommendations for Tetanus Toxoid, Reduced...
2010-06-17

spacer spacer APPENDIX A. Summary of Recommendations for Tetanus Toxoid, Reduced Diphtheria Toxoid and Acellular Pertussis Vaccine (Tdap) Use Among Adults The following...

Science.gov Websites

33
Cellular immunity in adolescents and adults following acellular pertussis vaccine administration.
2007-01-31

Cell-mediated immune (CMI) responses to an acellular pertussis vaccine administered to 49 subjects, a subset of participants in the National Institutes of Health-funded adult acellular pertussis vaccine efficacy trial, were evaluated and compared with antibody responses to ...

PubMed

34
Review of diphtheria, tetanus and pertussis vaccines in clinical development.
2011-05-01

Diphtheria, tetanus and pertussis vaccines have formed the cornerstone of childhood immunization programs for decades. Historically, these have comprised diphtheria and tetanus toxoids combined with inactivated whole-cell pertussis. More recently, advances have been made with the development of purified acellular ...

PubMed

35
Pertussis in adolescents and its prevention using Tdap vaccination.
2010-08-01

In industrialized nations, routine use of pertussis vaccines has shifted the burden of pertussis disease from middle childhood to one primarily affecting young infants, adolescents, and adults. Although generally not as severe as observed in infants, pertussis in adolescents and adults can be serious, and these ...

PubMed

36
CDC - General Questions and Answers about Adjuvants - Vaccine...
2011-08-07

visit this page: About CDC.gov. Vaccine Safety Vaccine Safety Vaccines Safety Basics Diphtheria, Tetanus, and Acellular Pertussis (DTaP) Haemophilus Influenzae Type B (Hib) Hib...

Science.gov Websites

37
Acellular pertussis vaccines and the role of pertactin and fimbriae.
2007-02-01

The introduction of acellular pertussis (Pa) vaccines in countries with a low uptake of whole-cell pertussis (Pw) vaccines has led to a dramatic reduction in pertussis disease. Diphtheria-tetanus-acellular pertussis (DTPa) ...

PubMed

38
Primary immunization series for infants: comparison of two-component acellular and standard whole-cell pertussis vaccines combined with diphtheria-tetanus toxoids.
1993-03-01

At 2 months of age, 145 infants were randomized to receive either a two-component acellular pertussis vaccine [lymphocytosis-promoting factor (LPF)/filamentous hemagglutinin (FHA)] or standard whole-cell pertussis vaccine, each combined with diphtheria-tetanus toxoids, as their primary ...

PubMed

39
Medical Care and Your 4- to 7-Month-Old

... generally given at the 4-month visit: second diphtheria, tetanus, acellular pertussis (DTaP) vaccine second Haemophilus influenzae ... 6-month visit, your baby may receive: third diphtheria, tetanus, acellular pertussis (DTaP) vaccine possibly the third ...

MedlinePLUS

40
Antibody persistence in UK pre-school children following primary series with an acellular pertussis-containing pentavalent vaccine given concomitantly with meningococcal group C conjugate vaccine, and response to a booster dose of an acellular pertussis-containing quadrivalent vaccine.
2009-06-30

This open-label, randomised, controlled study examined antibody persistence following infant vaccination at 2, 3 and 4 months of age with either an acellular pertussis, diphtheria, tetanus, inactivated poliovirus, Haemophilus influenzae type b (DT(5)aP-IPV-Hib; Pediacel) or a whole-cell pertussis (DTwP//Hib+oral ...

PubMed

First Page Previous Page 1 2 3 4 5 6 7 8 9 10 Next Page Last Page
 
First Page Previous Page 1 2 3 4 5 6 7 8 9 10 Next Page Last Page
 
41
Updated recommendations for use of tetanus toxoid, reduced diphtheria toxoid and acellular pertussis (Tdap) vaccine from the Advisory Committee on Immunization Practices, 2010.
2011-01-14

Despite sustained high coverage for childhood pertussis vaccination, pertussis remains poorly controlled in the United States. A total of 16,858 pertussis cases and 12 infant deaths were reported in 2009. Although 2005 recommendations by the Advisory Committee on Immunization Practices (ACIP) called for ...

PubMed

42
Long-term humoral and cell-mediated immunity after acellular pertussis vaccination compares favourably with whole-cell vaccines 6 years after booster vaccination in the second year of life.
2006-11-07

Humoral and cell-mediated immune responses (CMI) were evaluated in subjects 3 and 6 years after primary and booster vaccination with either three-component acellular (Pa) or whole-cell (Pw) vaccines. Low anti-pertussis toxin (PT) antibody levels confirmed the absence of pertussis disease, ...

PubMed

43
Boostrix: a reduced-dose acellular pertussis vaccine for use in adolescents and adults.
2009-10-01

Pertussis remains a serious problem in many countries. Even in countries with high vaccine coverage and a long vaccination history, pertussis outbreaks occur periodically. Rather than being a disease of young children, pertussis has shifted to affect adolescents and adults. Increased ...

PubMed

44
Effectiveness of an acellular pertussis vaccine in Japanese children during a non-epidemic period: a matched case-control study.
2008-05-12

The number of pertussis cases in Japan has decreased dramatically following the nationwide use of an acellular pertussis vaccine combined with diphtheria-tetanus toxoids (DTaP vaccines) which began in 1981. However, the effectiveness of the DTaP vaccine has not been ...

PubMed

46
Preventing Tetanus, Diphtheria, and Pertussis Among Adolescents: Use of Tetanus Toxoid, Reduced Diphtheria Toxoid and Acellular Pertussis Vaccines. Recommendations of the Advisory Committee on Immunization Practices (ACIP). Morbidity and Mortality Weekly Report, Vol. 55, No. RR-3, March 24, 2006.
2006-01-01

During spring 2005, two tetanus toxoid, reduced diphtheria toxoid and acellular pertussis vaccine (Tdap) products formulated for use in adolescents (and, for one product, use in adults) were licensed in the United States (BOOSTRIX, GlaxoSmithKline Biologi...

National Technical Information Service (NTIS)

47
Vaccines: Pubs/ACIP-list-supplmt/DTaP Recommendations
2011-08-07

CDC Guidelines September 26, 2003, Vol 52, #38 Notice to Readers: FDA Approval of Diphtheria and Tetanus Toxoids and Acellular Pertussis Vaccine Adsorbed, (INFANRIX®) for Fifth...

Science.gov Websites

48
Updated Recommendations for Use of Tetanus Toxoid, Reduced Diphtheria Toxoid and Acellular Pertussis (Tdap) Vaccine

... to DTaP or DTaP-IPV ( 11,12 ). All subjects had seroprotective antibody ... vaccines, with similar effects on cell-mediated immune responses 3.5 years ...

MedlinePLUS

49
UNIVERSITY OF ROCHESTER PSYCHOLOGY DOCTORAL INTERNS and

declines vaccine. Varicella History: If no confirmed disease history, serological test is required and recorded medical history for all personnel and members of the medical staff. The examination shall (CDC): � Proof of immunity against mumps � Recommend Td with Acellular Pertussis vaccine (Tdap

E-print Network

50
Recommended Immunization Schedules for Persons Aged 0 Through...
2011-08-07

upon the child's history of monovalent 2009 H1N1 vaccination (4). Use of tetanus and diphtheria toxoids, and acellular pertussis (Tdap) vaccine among children aged 7 through 10...

Science.gov Websites

51
National, State, and Local Area Vaccination Coverage among Adolescents...
2011-08-07

receive the following vaccines: meningococcal conjugate (MenACWY, 1 dose); tetanus, diphtheria, acellular pertussis (Tdap, 1 dose); and (for females) human papillomavirus (HPV, 3...

Science.gov Websites

52
From pertussis to meningococcal disease and back.
2011-04-01

From pertussis to meningococcal disease and back represents nearly 30 years of research at Porton, first at the Centre for Applied Microbiology and Research and latterly as part of the Health Protection Agency. I joined the group lead by Andy Robinson developing an acellular pertussis vaccine and was part of an ...

PubMed

53
Population dynamics of Bordetella pertussis in Finland and Sweden, neighbouring countries with different vaccination histories.
2006-09-20

Pertussis is an infectious disease of the respiratory tract in humans caused by Bordetella pertussis. Despite extensive vaccinations, pertussis has remained endemic and re-emerged. In Finland, a whole-cell pertussis vaccine has been used since 1952 with high coverage. In ...

PubMed

54
Acellular pertussis booster in adolescents induces Th1 and memory CD8+ T cell immune response.
2011-03-08

In a number of countries, whole cell pertussis vaccines (wcP) were replaced by acellular vaccines (aP) due to an improved reactogenicity profile. Pertussis immunization leads to specific antibody production with the help of CD4(+) T cells. In earlier studies in infants and young children, wcP ...

PubMed

55
Acellular Pertussis Booster in Adolescents Induces Th1 and Memory CD8+ T Cell Immune Response
2011-03-08

In a number of countries, whole cell pertussis vaccines (wcP) were replaced by acellular vaccines (aP) due to an improved reactogenicity profile. Pertussis immunization leads to specific antibody production with the help of CD4+ T cells. In earlier studies in infants and ...

PubMed Central

56
Effect of a prepregnancy pertussis booster dose on maternal antibody titers in young infants.
2011-07-01

To examine the influence of a pertussis booster vaccination on the transfer of maternal antibodies, 24 nonpregnant women received a tetanus, diphtheria, acellular pertussis booster vaccine between 2 consecutive pregnancies. Blood was drawn from mothers and off-spring. Efficient transplacental ...

PubMed

57
Antibody persistence against diphtheria, tetanus, pertussis, poliomyelitis and Haemophilus influenzae type b (Hib) in 5-6-year-old children after primary vaccination and first booster with a pentavalent combined acellular pertussis vaccine: immunogenicity and tolerance of a tetravalent combined acellular pertussis vaccine given as a second booster.
2004-03-29

The main objective of this study was to assess in 5-6-year-old French children (n=234) the persistence of antibodies induced by a primary series vaccination (at 2-4 months of age) and a first booster (at 12-16 months of age) with a pentavalent two-component acellular pertussis combined vaccine (DTacP-IPV-Hib; ...

PubMed

58
Development of a guinea-pig model for potency/immunogenicity evaluation of diphtheria, tetanus acellular pertussis (DTaP) and Haemophilus influenzae type b polysaccharide conjugate vaccines.
1996-01-01

We have evaluated a guinea pig model for assessing the immunogenicity of Haemophilus influenzae type b (Hib) polysaccharide-protein conjugate vaccines, acellular pertussis vaccine and combination vaccines-consisting of tetanus toxoid (TT), diphtheria toxoid (DT), acellular ...

PubMed

59
A murine model in which protection correlates with pertussis vaccine efficacy in children reveals complementary roles for humoral and cell-mediated immunity in protection against Bordetella pertussis.
1998-02-01

The results of phase 3 efficacy trials have shown that acellular and whole-cell pertussis vaccines can confer protection against whooping cough. However, despite the advances in vaccine development, clinical trials have not provided significant new information on the mechanism of protective immunity against ...

PubMed

60
Pertussis Vaccination for Health Care Workers
2008-07-01

Pertussis, an acute respiratory infection caused by Bordetella pertussis, classically manifests as a protracted cough illness. The incidence of pertussis in the United States has been increasing in recent years. Immunity wanes after childhood vaccination, leaving adolescents and adults susceptible to infection. The ...

PubMed Central

First Page Previous Page 1 2 3 4 5 6 7 8 9 10 Next Page Last Page
 
First Page Previous Page 1 2 3 4 5 6 7 8 9 10 Next Page Last Page
 
61
[Modern strains of Bordetella pertussis: immunobiological properties and vaccine improvement].

Strains of B. pertussis isolated from patients in Moscow in 2001-2005 as well as strains included in locally produced diphtheria-tetanus-whole cell pertussis (DTP) vaccine were studied. Nucleotide sequences in genes of pertactin and S1-subunit of pertussis toxin of isolated strains, their immunobiological ...

PubMed

62
Antibody responses to pertussis toxin display different kinetics after clinical Bordetella pertussis infection than after vaccination with an acellular pertussis vaccine.
2010-05-27

The measurement of IgG anti-pertussis toxin (IgG anti-PT) antibodies by ELISA is a frequently used method for studying the antibody responses after pertussis vaccination and after Bordetella pertussis infection. Such responses vary according to the different vaccines used as well as to the ...

PubMed

63
Pertussis before and after the introduction of acellular pertussis vaccines in Finland.
2009-07-21

In Finland, the whole-cell pertussis vaccine was replaced with acellular pertussis vaccine in the national immunisation schedule in 2005. Adolescent booster vaccinations were also included in the programme. The aim of this study was to evaluate the effects of these changes ...

PubMed

64
Pertussis immunization: an update
1997-06-01

A segment of chiropractic has historically opposed the practice of immunization. This opposition has been based on historical and philosophical precedent, but with little support from the scientific literature. Pertussis immunization has successfully controlled a disease with a prior history of high childhood morbidity. An evaluation of the literature fails to find supporting ...

PubMed Central

65
Persistence of antibodies at 5-6 years of age for children who had received a primary series vaccination with a pentavalent whole-cell pertussis vaccine and a first booster with a pentavalent acellular pertussis vaccine: immunogenicity and tolerance of second booster with a tetravalent acellular vaccine at 5-6 years of age.
2004-03-29

The main objective of this study was to assess in 5-6-year-old French children (n=162) the persistence of antibodies induced by a primary series vaccination (at 2-4 months of age) with a pentavalent whole-cell pertussis combined vaccine (DTwcP-IPV-Hib; Pentacoq) and a first booster (at 12-16 months of age) with a pentavalent ...

PubMed

66
Use of Diphtheria Toxoid-Tetanus Toxoid-Acellular Pertussis Vaccine...
2010-06-17

2000 CHAIRMAN John F. Modlin, M.D. Professor of Pediatrics and Medicine Dartmouth Medical School Lebanon, New Hampshire EXECUTIVE SECRETARY Dixie E. Snider, Jr., M.D.,...

Science.gov Websites

67
Recommended Immunization Schedules for Persons Aged 0--18 Years...
2010-06-17

against meningococcal disease for persons aged 2--18 years (6). The tetanus and diphtheria toxoids/tetanus and diphtheria toxoids and acellular pertussis vaccine (Td/Tdap)...

Science.gov Websites

68
Post-Marketing Safety Study of GSK Biological's Pediarix� Vaccine.
2008-09-10

Prophylaxis Against Diphtheria (D), Tetanus (T), Acellular Pertussis (aP), Hepatitis B (HBV) and Poliovirus Types 1, 2 & 3 (IPV)

ClinicalTrials.gov

69
Notice to Readers Recommended Childhood Immunization Schedule...
2010-06-17

in infants born to hepatitis B surface antigen (HBsAg)-negative mothers, the use of diphtheria and tetanus toxoids and acellular pertussis vaccine (DTaP), and the use of...

Science.gov Websites

70
Diphtheria and Tetanus Toxoids and Acellular Pertussis Vaccine ...

... 4.0 Description of Clinical Data Sources This supplement contains clinical data from two studies conducted in Germany (Studies APV-118 and APV-120) and one US ...

Center for Biologics Evaluation and Research (CBER)

71
Different IgG-subclass distributions after whole-cell and acellular pertussis infant primary vaccinations in healthy and pertussis infected children.
2011-07-29

The distribution of IgG-subclasses provides insight in the immunological mechanisms of protection against whooping cough. We investigated the effect of Dutch whole-cell pertussis and acellular pertussis vaccines administered in infancy on the IgG-subclass distributions in healthy children aged 12 months, 4 years ...

PubMed

72
Protective activity of the Bordetella pertussis BrkA autotransporter in the murine lung colonization model.
2008-06-26

This study examined the vaccine potential of the autotransporter protein BrkA of Bordetella pertussis in the sublethal intranasal murine respiratory challenge model of infection. Five different acellular pertussis (Pa) vaccines, containing different pertussis-component ...

PubMed

73
DTaP vaccines from north american vaccine (NAVA): composition and critical parameters.
1999-06-01

NAVA's acellular pertussis vaccine is based on highly purified pertussis toxin (PT) inactivated with H(2)O(2). PT was analysed using advanced biochemical methodology including mass spectroscopy (LC/MS), yielding mass and peptide mapping information on the subunits. Pertactin, adenylate cyclase, and Fim 1, 2 were ...

PubMed

74
Bordetella pertussis Clones Identified by Multilocus Variable-Number Tandem-Repeat Analysis
2010-02-01

Multilocus variable-number tandem-repeat analysis (MLVA) of 316 Bordetella pertussis isolates collected over 40 years from Australia and 3 other continents identified 66 MLVA types (MTs), including 6 predominant MTs. Typing of genes encoding acellular vaccine antigens showed changes that may be vaccine driven in 2 ...

PubMed Central

75
Immunogenicity and reactogenicity of co-administered tetanus-diphtheria-acellular pertussis (Tdap) and tetravalent meningococcal conjugate (MCV4) vaccines compared to their separate administration.
2010-12-04

In the United States, co-administration of tetanus toxoid, reduced diphtheria toxoid and acellular pertussis (Tdap) vaccine and tetravalent meningococcal conjugate vaccine (MCV4) is recommended in adolescents. In this clinical study, 1341 adolescents received Tdap (Boostrix� GlaxoSmithKline) and MCV4 ...

PubMed

76
Use of Models to Identify Cost-effective Interventions: Pertussis Vaccination for Pediatric Health Care Workers.
2011-08-15

Objective: Acellular pertussis vaccine is safe and effective in adults. An explicit recommendation for pertussis booster vaccination in pediatric health care workers is based on the importance of health care workers as a potential source of infection for patients. However, limited information ...

PubMed

77
DOI: 10.1542/peds.2004-1891 2005;115;461-467Pediatrics

-tetanus-acellular pertussis; HBV, hepatitis B vi- rus; IPV, inactivated polio vaccine; OPV, oral polio vaccine; MMR, measles protein conjugate vaccine [Hib-OMP]), hepatitis B vi- rus (HBV) vaccine, and measles-mumps-rubella (MMR. # Comvax (combination HBV-Hib conjugate ...

E-print Network

78
Quality control of diphtheria tetanus acellular pertussis combined (DTaP) vaccines in Japan.
2001-10-01

Diphtheria tetanus acellular pertussis combined (DTaP) vaccines have been successfully used in Japan by controlling their potencies and toxicities with animal models. In accordance with the recent practical introduction of DTaP vaccines of various formulations, a question has been raised in other nations as to the ...

PubMed

79
Modified intra-cerebral challenge assay for acellular pertussis vaccines: comparisons among whole cell and acellular vaccines.
2009-09-16

The modified intra-cerebral challenge assay for acellular pertussis vaccines is used in Japan, Korea, China and possibly other Asian countries as the potency assay for routine release of acellular pertussis (aP) and combination vaccines. National reference standards, ...

PubMed

80
Intranasal murine model of Bordetella pertussis infection. I. Prediction of protection in human infants by acellular vaccines.
1999-05-14

Bicomponent, tricomponent and pertactin DTPa vaccines were tested in sublethal aerosol, and lethal and sublethal intranasal murine Bordetella pertussis respiratory challenge models. Pertactin and bicomponent vaccines induced protective immunity against lethality but with little or no bacterial clearance. Intranasal challenge ...

PubMed

First Page Previous Page 1 2 3 4 5 6 7 8 9 10 Next Page Last Page
 
First Page Previous Page 1 2 3 4 5 6 7 8 9 10 Next Page Last Page
 
81
Differences of humoral and cellular immune response to an acellular pertussis booster in adolescents with a whole cell or acellular primary vaccination.
2008-10-11

To study the pertussis-specific immune response of adolescents with different prevaccination schedules, we measured the humoral and cell-mediated immunity (CMI) to pertussis antigens before and after a five-component Tdap booster vaccination in 78 adolescents, who had previously received either five doses of a two-component ...

PubMed

82
Post-licensure comparison of the safety profile of diphtheria/tetanus/whole cell pertussis/haemophilus influenza type b vaccine and a 5-in-1 diphtheria/tetanus/acellular pertussis/haemophilus influenza type b/polio vaccine in the United Kingdom.
2010-08-26

General practitioner consultation data were used to compare the reactogenicity in infants of a 5-in-1 acellular pertussis vaccine (DTaP(5)/Hib/IPV) introduced in the United Kingdom in 2004 to the 4-in-1 whole cell-pertussis vaccine (DTwP/Hib) that it replaced. For each ...

PubMed

83
IgG responses after booster vaccination with different pertussis vaccines in Dutch children 4 years of age: effect of vaccine antigen content.
2009-09-01

Since whooping cough is reemerging in the Netherlands from 1996 onwards, several changes in the national immunization program have been implemented regarding the pertussis vaccinations. The aim of this study is to investigate IgG responses in whole cell (wP) and acellular (aP) pertussis vaccine ...

PubMed

84
Combined, reduced-antigen content tetanus, diphtheria, and acellular pertussis vaccine (Boostrix): a review of its use as a single-dose booster immunization in individuals aged 10-64 years in the US.
2009-01-01

Boostrix is a three-pertussis component, combined, reduced-antigen content tetanus, diphtheria, and acellular pertussis (Tdap) booster vaccine administered as a single intramuscular dose in adolescents or adults aged 10-64 years. Large, well designed trials conducted in the US in adolescents aged 10-18 years and in ...

PubMed

85
Update on Available Vaccines in India: Report of the APPA VU 2010: I.
2011-03-05

The Asia Pacific Pediatric Association Vaccinology Update 2010 was held in Mumbai on November 13-14, 2010 to discuss the latest information on burden of infectious diseases, recent developments in vaccines and their impact on immunization practices against infectious diseases occurring in Indian children. During the conference the importance of including conjugate Haemophilus ...

PubMed

86
Prevention of Pertussis, Tetanus, and Diptheria Among Pregnant and Postpartum Women and Their Infants. Recommendations of the Advisory Committee on Immunization Practices (ACIP). Morbidity and Mortality Weekly Report, Vol. 57, No. RR-4, May 30, 2008.
2008-01-01

In 2005, two tetanus toxoid, reduced diphtheria toxoid, and acellular pertussis (Tdap) vaccines were licensed and recommended for use in adults and adolescents in the United States: ADACEL (sanofi pasteur, Swiftwater, Pennsylvania), which is licensed for ...

National Technical Information Service (NTIS)

87
First report and detailed characterization of B. pertussis isolates not expressing Pertussis Toxin or Pertactin.
2009-08-08

Bordetella pertussis isolates not expressing Pertussis Toxin (PT) or Pertactin (PRN) have been collected, for the first time in 2007, in France, a highly vaccinated country with acellular vaccines. Non-expression was due to deletion of the entire ptx locus, to IS481 insertion in the prn gene or ...

PubMed

88
Bordetella pertussis infection or vaccination substantially protects mice against B. bronchiseptica infection.
2009-08-26

Although B. bronchiseptica efficiently infects a wide range of mammalian hosts and efficiently spreads among them, it is rarely observed in humans. In contrast to the many other hosts of B. bronchiseptica, humans are host to the apparently specialized pathogen B. pertussis, the great majority having immunity due to vaccination, infection or both. Here we ...

PubMed

89
Bordetella pertussis Infection or Vaccination Substantially Protects Mice against B. bronchiseptica Infection
2009-08-26

Although B. bronchiseptica efficiently infects a wide range of mammalian hosts and efficiently spreads among them, it is rarely observed in humans. In contrast to the many other hosts of B. bronchiseptica, humans are host to the apparently specialized pathogen B. pertussis, the great majority having immunity due to vaccination, infection or both. Here we ...

PubMed Central

90
T- and B-Cell-Mediated Protection Induced by Novel, Live Attenuated Pertussis Vaccine in Mice. Cross Protection against Parapertussis
2010-04-15

BackgroundDespite the extensive use of efficacious vaccines, pertussis still ranks among the major causes of childhood mortality worldwide. Two types of pertussis vaccines are currently available, whole-cell, and the more recent acellular vaccines. Because of reduced ...

PubMed Central

91
Reduced-antigen-content-diphtheria-tetanus-acellular-pertussis and inactivated polio vaccine as a booster for adolescents 10 to 14 years of age.
2005-03-22

High rates of pertussis disease in adolescents suggest that additional boosting against pertussis would be beneficial. A combined acellular-pertussis-containing booster vaccine (dTpa-IPV; Boostrixtrade mark Polio, n =440) was compared to separately administered dTpa (Boostrixtrade mark) and inactivated polio virus ...

PubMed

92
Comparison of acellular (B type) and whole-cell pertussis-component diphtheria-tetanus-pertussis vaccines as the first booster immunization in 15- to 24-month-old children.
1992-12-01

We compared an acellular (B type) pertussis-component diphtheria-tetanus-pertussis (DTP-Ac) vaccine containing equal amounts of filamentous hemagglutinin and lymphocytosis-promoting factor with a conventional whole-cell vaccine as the first booster immunization in 162 healthy children 15 to 24 ...

PubMed

93
Booster vaccination against pertussis in Chinese children at six years of age using reduced antigen content diphtheria-tetanus-acellular pertussis vaccine (Boostrix()).
2010-03-01

Pertussis continues to circulate in Chinese communities and older children, adolescents and adults are sources of infection for unprotected infants. Two studies conducted in Jiangsu Province in the People's Republic of China assessed the immunogenicity, reactogenicity and safety of Boostrix(), a combined reduced antigen content diphtheria-tetanus-acellular ...

PubMed

94
Development of an IgY-based rocket-immunoelectrophoresis for identity monitoring of Pertussis vaccines.
2011-05-04

An important step in vaccine production and quality control is the analysis of identity of different lots. For that purpose chicken was immunized with acellular Pertussis components (Pertussis toxoid, Filamenteous haemagglutinin, Pertactin, Fimbriae 2/3 antigen). The resulting antibodies (IgY) were non-invasive ...

PubMed

95
Randomized Trial on the Safety, Tolerability, and Immunogenicity of MenACWY-CRM, an Investigational Quadrivalent Meningococcal Glycoconjugate Vaccine, Administered Concomitantly with a Combined Tetanus, Reduced Diphtheria, and Acellular Pertussis Vaccine in Adolescents and Young Adults? �
2010-04-17

This study evaluated the safety, tolerability, and immunogenicity of an investigational quadrivalent meningococcal conjugate vaccine, MenACWY-CRM, when administered concomitantly with a combined tetanus, reduced diphtheria, and acellular pertussis (Tdap) vaccine, in subjects aged 11 to 25 years. Subjects received ...

PubMed Central

96
Randomized trial on the safety, tolerability, and immunogenicity of MenACWY-CRM, an investigational quadrivalent meningococcal glycoconjugate vaccine, administered concomitantly with a combined tetanus, reduced diphtheria, and acellular pertussis vaccine in adolescents and young adults.
2010-02-17

This study evaluated the safety, tolerability, and immunogenicity of an investigational quadrivalent meningococcal conjugate vaccine, MenACWY-CRM, when administered concomitantly with a combined tetanus, reduced diphtheria, and acellular pertussis (Tdap) vaccine, in subjects aged 11 to 25 years. Subjects received ...

PubMed

97
Evaluation of components of X-ray irradiated 7-valent pneumococcal conjugate vaccine and pneumococcal vaccine polyvalent and X-ray and gamma-ray irradiated acellular pertussis component of DTaP vaccine products
2004-09-01

Samples of pneumococcal vaccine polyvalent, 7-valent pneumococcal conjugate vaccine, and two different diphtheria and tetanus toxoids and acellular pertussis vaccines adsorbed were irradiated with X-rays and/or gamma-rays (Co-60). Mouse IgG and IgM antibody responses (ELISA) for types 9V, 14, ...

NASA Astrophysics Data System (ADS)

98
Lipopolysaccharide Analogs Improve Efficacy of Acellular Pertussis Vaccine and Reduce Type I Hypersensitivity in Mice?
2007-07-09

Pertussis is an infectious disease of the respiratory tract that is caused by the gram-negative bacterium Bordetella pertussis. Although acellular pertussis (aP) vaccines are safe, they are not fully effective and thus require improvement. In contrast to whole-cell ...

PubMed Central

99
Variation in Clinician Recommendations for Multiple Injections During Adoption of Inactivated Polio Vaccine

Variation in Clinician Recommendations for Multiple Injections During Adoption of Inactivated Polio/content/full/107/4/e49; immunizations, vaccines, pro- vider practices, practice variation, inactivated polio vac- cine. ABBREVIATIONS. IPV, inactivated polio vaccine; DTaP, diphthe- ria-tetanus-acellular pertussis

E-print Network

100
Effectiveness of the whole-cell pertussis vaccine produced in Poland against different Bordetella parapertussis isolates in the mouse intranasal challenge model.
2011-06-12

The aim of the study was to evaluate the effectiveness of the whole-cell pertussis vaccine produced locally and routinely used in Poland in the elimination of Bordetella parapertussis strains from the lungs and trachea of a mouse model. We found that the average protective effect against B. parapertussis in the lungs of mice immunized with the whole-cell ...

PubMed

First Page Previous Page 1 2 3 4 5 6 7 8 9 10 Next Page Last Page
 
First Page Previous Page 1 2 3 4 5 6 7 8 9 10 Next Page Last Page
 
101
Cellular Immune Responses of Preterm Infants after Vaccination with Whole-Cell or Acellular Pertussis Vaccines?
2010-02-16

Based on studies reporting specific antibody titers, it is recommended to vaccinate preterm infants against Bordetella pertussis according to their chronological age. However, as specific T-cell responses also are involved in the protection against B. pertussis, we have determined whether highly preterm infants (<31 weeks) are able ...

PubMed Central

102
Licensure of a diphtheria and tetanus toxoids and acellular pertussis adsorbed, inactivated poliovirus, and haemophilus B conjugate vaccine and guidance for use in infants and children.
2008-10-01

On June 20, 2008 the Food and Drug Administration (FDA) licensed a combined diphtheria and tetanus toxoids and acellular pertussis adsorbed (DTaP), inactivated poliovirus vaccine (IPV), and Haemophilus influenzae type b conjugate (tetanus toxoid [TT] conjugate) vaccine, DTaP-IPV/Hib (Pentacel, Sanofi Pasteur, ...

PubMed

103
Immunogenicity and protective efficacy of a recombinant filamentous haemagglutinin from Bordetella pertussis
2006-06-01

Bordetella pertussis is the causative agent of whooping cough, a major childhood pathogen; acellular vaccines consisting of purified B. pertussis antigens such as filamentous haemagglutinin (FHA) are commonly used to prevent pertussis. Despite the importance of FHA in B. ...

PubMed Central

104
Antibody and cell-mediated immune responses to booster immunization with a new acellular pertussis vaccine in school children.
1998-10-01

235 healthy 10-12 years old school children were randomly immunized with either a booster dose of diphtheria-tetanus-acellular pertussis (dTap) or diphtheria-tetanus (dT) vaccine. For this booster immunization designed for school children and adults, the quantities of Bordetella pertussis antigens in the dTap ...

PubMed

105
Acellular pertussis vaccine boosters combined with diphtheria and tetanus toxoid boosters for adolescents: safety and immunogenicity assessment when preceded by different 5-dose DTaP/DTwP schedules.
2006-09-01

A sixth dose of tetanus, diphtheria, acellular pertussis (Tdap) vaccine in adolescents might produce a differing reactogenicity and/or immunogenicity response depending on the composition of the 5 prior doses of DTaP or DT-whole cell pertussis (DTwP) vaccine. Reactions and immune responses ...

PubMed

106
Safety and immunogenicity of a tetanus toxoid, reduced diphtheria toxoid, and acellular pertussis vaccine when co-administered with influenza vaccine in adults.
2009-12-31

Annual vaccination with trivalent influenza vaccine (TIV), and a single dose of tetanus toxoid-reduced diphtheria toxoid-acellular pertussis (Tdap) vaccine, are both recommended for adults in the US. This study was conducted to obtain information on the safety and immunogenicity of ...

PubMed

107
Cross-species protection mediated by a Bordetella bronchiseptica strain lacking antigenic homologs present in acellular pertussis vaccines.
2010-02-22

The Bordetella species are Gram-negative bacterial pathogens that are characterized by long-term colonization of the mammalian respiratory tract and are causative agents of respiratory diseases in humans and animals. Despite widespread and efficient vaccination, there has been a world-wide resurgence of pertussis, which remains the leading cause of ...

PubMed

108
Cross-Species Protection Mediated by a Bordetella bronchiseptica Strain Lacking Antigenic Homologs Present in Acellular Pertussis Vaccines?
2010-05-22

The Bordetella species are Gram-negative bacterial pathogens that are characterized by long-term colonization of the mammalian respiratory tract and are causative agents of respiratory diseases in humans and animals. Despite widespread and efficient vaccination, there has been a world-wide resurgence of pertussis, which remains the leading cause of ...

PubMed Central

109
Kinetics and sensitivity of ELISA IgG pertussis antitoxin after infection and vaccination with Bordetella pertussis in young children.
2009-11-01

Sera from 96 young children in a vaccine trial were analysed for kinetics of ELISA IgG anti-pertussis toxin (anti-PT) after a laboratory-verified pertussis infection. The antibody decay curves after infection were biphasic and similar in shape to those after vaccination. The change from a rapid to a slower decay ...

PubMed

110
Collaborative study on a Guinea pig serological method for the assay of acellular pertussis vaccines.
2009-10-01

An international collaborative study (coded BSP083) was performed under the aegis of the Biological Standardisation Programme supported by the Council of Europe and the European Commission, with the aim of replacing the in vivo challenge assays for potency determination of combined acellular pertussis (aP) vaccines by a refined ...

PubMed

111
Production and secretion of pertussis toxin subunits in Bacillus subtilis.
1990-03-01

Pertussis toxin (PT) is a major component of today's acellular whooping cough vaccines. The use of acellular vaccines is predicted to increase sharply in the near future. There is therefore a need to produce PT in a way that makes its purification as easy as possible. Our approach was to ...

PubMed

112
Femoral neuropraxia after vaccination in a 3-month-old infant: a case report.
2011-05-01

We report an incidence of a 3-month-old infant who developed femoral neuropraxia after vaccination (diphtheria, tetanus and acellular pertussis/inactivated poliovirus/haemophilus influenzae type B vaccine) in the thigh. To the best of our knowledge, femoral nerve injury after vaccination has ...

PubMed

113
Immunogenicity of a combination vaccine containing diphtheria toxoid, tetanus toxoid, three-component acellular pertussis, hepatitis B, inactivated polio virus, and Haemophilus influenzae type b when given concomitantly with 13-valent pneumococcal conjugate vaccine.
2011-06-23

Two randomized trials of 13-valent pneumococcal conjugate vaccine (PCV13) relative to PCV7 evaluated the immune responses of coadministered antigens comprising Infanrix(�) hexa/Infanrix(�)-IPV+Hib (diphtheria, tetanus, 3-component acellular pertussis, hepatitis B, inactivated poliovirus, and Haemophilus influenzae type b). After ...

PubMed

114
Kinrix: a new combination DTaP-IPV vaccine for children aged 4-6 years.
2008-11-01

Combination vaccines allow the administration of multiple vaccine antigens without the need for multiple injections. Recently, a combined diphtheria toxoid, tetanus toxoid, acellular pertussis and inactivated poliomyelitis vaccine (DTaP-IPV), Kinrix, has been licensed in the USA for use as the ...

PubMed

115
A randomised controlled trial with a diphtheria-tetanus-acellular pertussis (dTpa) vaccine in adults.
2000-04-14

The aim of this assessor-blinded trial was to compare the immunogenicity and reactogenicity of a candidate diphtheria, tetanus toxoids and acellular pertussis vaccine with reduced antigen content for diphtheria and pertussis (dTpa) with a licensed reduced adult-type diphtheria-tetanus vaccine ...

PubMed

116
Mass Spectrometric Analysis of Multiple Pertussis Toxins and Toxoids
2010-05-23

Bordetella pertussis (Bp) is the causative agent of pertussis, a vaccine preventable disease occurring primarily in children. In recent years, there has been increased reporting of pertussis. Current pertussis vaccines are acellular and consist of Bp ...

PubMed Central

117
Mass spectrometric analysis of multiple pertussis toxins and toxoids.
2010-05-23

Bordetella pertussis (Bp) is the causative agent of pertussis, a vaccine preventable disease occurring primarily in children. In recent years, there has been increased reporting of pertussis. Current pertussis vaccines are acellular and consist of Bp ...

PubMed

118
Identifying long-term memory B-cells in vaccinated children despite waning antibody levels specific for Bordetella pertussis proteins.
2010-12-25

Whooping cough is a respiratory disease caused by Bordetella pertussis. Since the 1950s in developed countries pertussis vaccinations are included in the national immunization program. However, antibody levels rapidly wane after both whole cell and acellular pertussis ...

PubMed

119
[Vaccination schedule of the Spanish Association of Pediatrics: recommendations 2005].
2005-02-01

The Advisory Committee on Vaccines of the Spanish Association of Pediatrics provides information and comments on the new developments in vaccines that have taken place in 2004 and recommends a few modifications to the Immunization Schedule for 2005. Concerning the meningococcal C vaccine, no change is made to the possibility of ...

PubMed

120
The epidemiology of pertussis in Germany: past and present
2009-02-25

BackgroundCurrent and past pertussis epidemiology in the two parts of Germany is compared in the context of different histories of vaccination recommendations and coverage to better understand patterns of disease transmission.MethodsAvailable regional pertussis surveillance and vaccination coverage data, ...

PubMed Central

First Page Previous Page 1 2 3 4 5 6 7 8 9 10 Next Page Last Page
 
First Page Previous Page 1 2 3 4 5 6 7 8 9 10 Next Page Last Page
 
121
Antibodies recognizing protective pertussis toxin epitopes are preferentially elicited by natural infection versus acellular immunization.
2011-04-20

Despite more than 50 years of vaccination, disease caused by the bacterium Bordetella pertussis persists, with rates increasing in industrialized countries over the past decade. This rise may be attributed to several factors, including increased surveillance, emergence of vaccine escape variants, waning immunity in adults, and the ...

PubMed

122
The distribution over time of costs and social net benefits for pertussis immunization programs.
2009-03-18

The cost of a six-dose pertussis immunization programs for children and adolescents is investigated in relation to estimators of the price of acellular vaccine, the value of a child's life, levels of vaccination rate and discount rates. We compare the cost of the program maintained over time at 90% with three ...

PubMed

123
Revised diphtheria, tetanus, and pertussis (DTP/DTaP/DT) vaccine information materials--CDC. Notice.
1998-01-01

Under the National Childhood Vaccine Injury Act (42 U.S.C section 300aa-26), the CDC must develop vaccine information materials that health care providers, either public or private, are required to distribute to patients/parents prior to administration of each dose of specific vaccines. On September 13, 1996, CDC published a notice in ...

PubMed

124
Antibody Response Patterns to Bordetella pertussis Antigens in Vaccinated (Primed) and Unvaccinated (Unprimed) Young Children with Pertussis?
2010-05-24

In a previous study, it was found that the antibody response to a nonvaccine pertussis antigen in children who were vaccine failures was reduced compared with the response in nonvaccinated children who had pertussis. In two acellular pertussis vaccine efficacy trials in ...

PubMed Central

125
Antibody response patterns to Bordetella pertussis antigens in vaccinated (primed) and unvaccinated (unprimed) young children with pertussis.
2010-03-24

In a previous study, it was found that the antibody response to a nonvaccine pertussis antigen in children who were vaccine failures was reduced compared with the response in nonvaccinated children who had pertussis. In two acellular pertussis vaccine efficacy trials in ...

PubMed

126
A DTaP-IPV//PRP?T vaccine (Pentaxim�): a review of 16 years' clinical experience.
2011-07-12

Owing to their low reactogenicity, confirmed efficacy and availability in combination vaccines, acellular pertussis (aP)-inactivated poliovirus (IPV) combined vaccines are now included in various national immunization programs worldwide. We provide an overview of 16 years of clinical experience with a diphtheria ...

PubMed

127
Changes in DT vaccine frequency and indications for use following introduction of DTaP vaccine.
2010-05-06

Our population-based study among HMO members under seven years of age in 1993-2000 showed that frequency of diphtheria and tetanus toxoid vaccine (DT) use declined significantly following the introduction of acellular pertussis-containing (DTaP) vaccine. We also observed changes in indications for DT following the ...

PubMed

128
Live Attenuated B. pertussis as a Single-Dose Nasal Vaccine against Whooping Cough
2006-07-07

Pertussis is still among the principal causes of death worldwide, and its incidence is increasing even in countries with high vaccine coverage. Although all age groups are susceptible, it is most severe in infants too young to be protected by currently available vaccines. To induce strong protective immunity in neonates, we have ...

PubMed Central

129
Acellular Bordetella pertussis vaccine enhances mucosal interleukin-10 production, induces apoptosis of activated Th1 cells and attenuates colitis in G?i2-deficient mice
2005-07-01

Mice deficient for the inhibitory G protein subunit ?2 (G?i2?/?) spontaneously develop a progressive inflammatory bowel disease resembling ulcerative colitis, and have a T helper 1 (Th1)-dominated immune response prior to onset of colitis, which is further augmented after the onset of disease. The present study was performed to investigate whether the ...

PubMed Central

130
Immunogenicity and reactogenicity of a single dose of a diphtheria--tetanus--acellular pertussis component vaccine (DTaP) compared to a diphtheria--tetanus toxoid (Td) and a diphtheria toxoid vaccine (d) in adults.
2001-04-30

We compared immunogenicity and reactogenicity of a single dose of DTaP vaccine (containing tetanus and diphtheria toxoids and four acellular pertussis antigens) with conventional Td- or d-vaccines in 180 German adults. Antibody values against diphtheria and tetanus toxin and against the ...

PubMed

131
Outer membrane vesicles as acellular vaccine against pertussis.
2008-07-18

In this study the development and evaluation of outer membrane vesicles (OMVs) obtained from Bordetella pertussis as vaccines against pertussis disease is described. SDS-PAGE, immunoblot techniques and gel electrophoresis associated to tandem mass spectrometry were used to describe the composition of the OMVs obtained from B. ...

PubMed

132
Acellular Pertussis Vaccine Protects against Exacerbation of Allergic Asthma Due to Bordetella pertussis in a Murine Model
2005-03-01

The prevalence of asthma and allergic disease has increased in many countries, and there has been speculation that immunization promotes allergic sensitization. Bordetella pertussis infection exacerbates allergic asthmatic responses. We investigated whether acellular pertussis vaccine (Pa) enhanced or prevented B. ...

PubMed Central

133
Safety and immunogenicity of a fully liquid vaccine containing five-component pertussis-diphtheria-tetanus-inactivated poliomyelitis-Haemophilus influenzae type b conjugate vaccines administered at two, four, six and 18 months of age
2007-07-01

OBJECTIVEThe safety, immunogenicity and lot consistency of a fully liquid, five-component acellular pertussis combination vaccine, comprised of diphteria, tetanus and acellular pertussis, inactivated polio vaccine, Haemophilus influenzae type b (DTaP-IPV-Hib [Pediacel, ...

PubMed Central

134
The utility of seroepidemiology for tracking trends in pertussis infection.
2009-09-01

Comparing pertussis epidemiology over time and between countries is confounded by differences in diagnostic and notification practices. Standardized serological methods applied to population-based samples enhance comparability. Population prevalence of different levels of pertussis toxin IgG (PT IgG) antibody, measured by standardized methods, were ...

PubMed

135
Evaluation of endotoxin content of diphtheria-tetanus-acellular pertussis combined (DTaP) vaccines that interfere with the bacterial endotoxin test.
2003-05-16

Applicability of the endotoxin test to diphtheria-tetanus-acellular pertussis combined (DTaP) vaccines was examined. We found some DTaP vaccines that strongly interfered with Limulus amoebocyte lysate (LAL) activity of endotoxin without affecting lethal activity of endotoxin in D-galactosamine-treated mice. LAL ...

PubMed

136
Immunogenicity of a two-component (PT & FHA) acellular pertussis vaccine in various combinations.
2008-09-02

Immunogenicity data for the pertussis components of the French diphtheria-tetanus-two component acellular pertussis vaccine (DTaP(2Fr)) obtained after primary series of immunizations were compiled from 75 study groups comprising 36 clinical trials or vaccination programs conducted between 1987 ...

PubMed

137
Long-term immunity against pertussis induced by a single nasal administration of live attenuated B. pertussis BPZE1.
2010-08-13

Duration of vaccine-induced immunity plays a key role in the epidemiology and in the pattern of transmission of a vaccine-preventable disease. In the case of whooping cough, its re-emergence has been attributed, at least partly, to the waning of immunity conferred by current pertussis vaccines. We have recently ...

PubMed

138
Impaired long-term maintenance and function of Bordetella pertussis specific B cell memory.
2010-07-15

Frequent occurrence of whooping cough in vaccinated populations suggests limited duration of vaccine-induced immunological memory. To investigate peculiarities in B cell memory specific for pertussis antigens P.69 pertactin (P.69 Prn), pertussis toxin (Ptx) and filamentous hemagglutinin (FHA), we monitored the ...

PubMed

139
Pentacel - Diphtheria and Tetanus Toxoids and Acellular Pertussis ...

... 10366 103666/5041) describing modifications to the potency assay for the (' , . 6/5036, describing modifications to the assays for all pertussis antigen~ and ...

Center for Biologics Evaluation and Research (CBER)

140
Pentacel - Diphtheria and Tetanus Toxoids and Acellular Pertussis ...

... Sample size and statistical power calculations were based on overall age-specific pertussis rates during 2004-2006, projection of Pentacel market share ...

Center for Biologics Evaluation and Research (CBER)

First Page Previous Page 1 2 3 4 5 6 7 8 9 10 Next Page Last Page
 
First Page Previous Page 1 2 3 4 5 6 7 8 9 10 Next Page Last Page
 
141
Date: August 12, 2009

... 15 Lf), tetanus toxoid (5 Lf) and acellular pertussis antigens (10 ?g detoxified pertussis toxin, 5 ?g filamentous hemagglutinin, 3 ?g pertactin, and 5 ?g ...

Center for Biologics Evaluation and Research (CBER)

142
Health-state valuations for pertussis: methods for valuing short-term health states
2005-03-21

BackgroundThe incidence of reported adolescent and adult pertussis continues to rise in the United States. Acellular pertussis vaccines for adolescents and adults have been developed and may be available soon for use in the U.S. Our objectives were: (1) to describe patient valuations of ...

PubMed Central

143
DTPa-HBV-IPV/Hib Vaccine (Infanrix hexa): A Review of its Use as Primary and Booster Vaccination.
2010-05-28

Infanrix hexa, administered intramuscularly, is a diphtheria, tetanus, acellular pertussis, hepatitis B (HBV), inactivated poliomyelitis and Haemophilus influenzae type b (Hib) conjugate vaccine, indicated for primary and booster vaccination of infants. Infanrix hexa should be administered as a two- or three-dose ...

PubMed

144
Pulsed-field gel electrophoresis, pertactin, pertussis toxin S1 subunit polymorphisms, and surfaceome analysis of vaccine and clinical Bordetella pertussis strains.
2007-08-15

To add new insight to our previous work on the molecular epidemiology of Bordetella pertussis in Argentina, the prn and ptxS1 gene sequences and pulsed-field gel electrophoresis (PFGE) profiles of 57 clinical isolates obtained during two periods, 1969 to 1989 and 1997 to 2006, were analyzed. Non-vaccine-type ptxS1A was detected in isolates obtained since ...

PubMed

145
Spotlight on DTPa-HBV-IPV/Hib Vaccine (Infanrix hexa).
2010-10-01

Infanrix hexa, administered intramuscularly, is a diphtheria, tetanus, acellular pertussis, hepatitis B (HBV), inactivated poliomyelitis and Haemophilus influenzae type b (Hib) conjugate vaccine, indicated for primary and booster vaccination of infants. Infanrix hexa should be administered as a two- or three-dose ...

PubMed

146
Generation of plant-derived recombinant DTP subunit vaccine.
2009-04-17

The current diphtheria-tetanus-pertussis (DTP) pediatric vaccine is produced from the corresponding pathogenic bacteria Corynebacterium diphtheriae, Clostridium tetani and Bordetella pertussis; five injected doses of DTaP (acellular) vaccine are required for every child in the standard US ...

PubMed

147
Predicted long-term persistence of pertussis antibodies in adolescents after an adolescent and adult formulation combined tetanus, diphtheria, and 5-component acellular pertussis vaccine, based on mathematical modeling and 5-year observed data.
2008-06-02

In a clinical trial, adolescents who had received a booster dose of reduced dose diphtheria-tetanus-5-component acellular pertussis vaccine (Adacel, Tdap) 5 years earlier maintained increased antibody concentrations to all antigens compared with pre-vaccination values. Observed data were applied to several ...

PubMed

148
Tdap5 vaccine (Covaxis): a review of its use as a single-booster immunization for the prevention of tetanus, diphtheria, and pertussis in children (aged 4 years), adolescents, and adults.
2010-12-01

Covaxis (also licensed as Triaxis or Adacel in individual countries) is a combined tetanus toxoid, reduced diphtheria toxoid, five component acellular pertussis (namely detoxified pertussis toxin, filamentous hemagglutinin, pertactin, and fimbriae types 2 and 3) vaccine for the prevention of diphtheria, tetanus, ...

PubMed

149
Spotlight on Tdap? vaccine (Covaxis�) as a single-booster immunization for the prevention of tetanus, diphtheria, and pertussis: in children (aged ?4 years), adolescents, and adults.
2011-04-01

Covaxis� (also licensed as Triaxis� or Adacel� in individual countries) is a Tdap? (i.e. combined tetanus toxoid, reduced diphtheria toxoid, five component acellular pertussis [namely detoxified pertussis toxin, filamentous hemagglutinin, pertactin, and fimbriae types 2 and 3]) vaccine for the prevention of ...

PubMed

150
Immunogenicity and safety of a combined diphtheria, tetanus, 5-component acellular pertussis, inactivated poliomyelitis, Haemophilus type b conjugate vaccine when administered concurrently with a pneumococcal conjugate vaccine: a randomized, open-label, phase 3 study.
2010-07-06

A phase 3 randomized, multicenter study evaluated the safety and immunogenicity of a combined diphtheria, tetanus, 5-component acellular pertussis, inactivated poliomyelitis, Haemophilus influenzae type b conjugate vaccine (DTaP(5)-IPV/Hib) administered at the same visit with 7-valent pneumococcal conjugate vaccine ...

PubMed

151
Pertussis serology: assessment of IgG anti-PT ELISA for replacement of the CHO cell assay.
2010-09-02

Two types of serological assays are commonly used for the assessment of pertussis vaccine-induced antibodies; the Chinese hamster ovary cell (CHO cell) assay and the immunoglobulin G (IgG) anti pertussis toxin (PT) enzyme-linked immunosorbent assay (IgG anti-PT ELISA). Recently, both the techniques have been modified to improve ...

PubMed

152
Weakened Immune Systems

... effects in children with weakened immune systems include diphtheria, tetanus, and acellular pertussis; hepatitis A; hepatitis B; ...

MedlinePLUS

153
Tetanus Toxoid, Reduced Diphtheria Toxoid and Acellular Pertussis ...

... Immunization with diphtheria toxoid does not, however, eliminate carriage of C diphtheriae in the pharynx, nose, or on the skin. ...

Center for Biologics Evaluation and Research (CBER)

154
Diphtheria and Tetanus Toxoids and Acellular Pertussis ...

... Thimerosal, aluminum and free formaldehyde content, sterility and general ... Tripediam is compounded, filled, labeled, packaged, and released by ...

Center for Biologics Evaluation and Research (CBER)

155
Acellular pertussis vaccination facilitates Bordetella parapertussis infection in a rodent model of bordetellosis
2010-07-07

Despite over 50 years of population-wide vaccination, whooping cough incidence is on the rise. Although Bordetella pertussis is considered the main causative agent of whooping cough in humans, Bordetella parapertussis infections are not uncommon. The widely used acellular whooping cough vaccines (aP) are comprised ...

PubMed Central

156
Immunodominance in mouse and human CD4+ T-cell responses specific for the Bordetella pertussis virulence factor P.69 pertactin.
2008-11-17

P.69 pertactin (P.69 Prn), an adhesion molecule from the causative agent of pertussis, Bordetella pertussis, is present in cellular and most acellular vaccines that are currently used worldwide. Although both humoral immunity and cellular immunity directed against P.69 Prn have been implicated in protective immune ...

PubMed

157
Immunodominance in Mouse and Human CD4+ T-Cell Responses Specific for the Bordetella pertussis Virulence Factor P.69 Pertactin?
2009-02-17

P.69 pertactin (P.69 Prn), an adhesion molecule from the causative agent of pertussis, Bordetella pertussis, is present in cellular and most acellular vaccines that are currently used worldwide. Although both humoral immunity and cellular immunity directed against P.69 Prn have been implicated in protective immune ...

PubMed Central

158
Comparison of recombinant and native pertactin of Bordetella pertussis.
2011-01-07

Bordetella pertussis pertactin (Prn) is an important attachment factor and protective immunogen, which serves as a component in most acellular pertussis vaccines (APVs). Here, we over-expressed recombinant Prn (r-Prn) without an affinity tag using an Escherichia coli expression system. Compared to the native Prn ...

PubMed

159
Societal impact of combination vaccines: experiences of physicians, nurses, and parents.
2008-03-14

Crowded immunization schedules can result in missed or delayed dosing. Combination vaccines help immunize children on time, limit the required number of injections, and allow new vaccines to be added to the schedule. In the United States, a pentavalent vaccine combining diphtheria, tetanus toxoids, and acellular ...

PubMed

160
Impact of infant and preschool pertussis vaccinations on memory B-cell responses in children at 4 years of age.
2011-06-12

Whooping cough, caused by Bordetella pertussis, is reemerging in the vaccinated population. Antibody levels to pertussis antigens wane rapidly after both whole-cell (wP) and acellular pertussis (aP) vaccination and protection may largely depend on long-term B- and T-cell ...

PubMed

First Page Previous Page 1 2 3 4 5 6 7 8 9 10 Next Page Last Page
 
First Page Previous Page 1 2 3 4 5 6 7 8 9 10 Next Page Last Page
 
161
IMPERFECT VACCINES AND THE EVOLUTION OF PATHOGENS CAUSING ACUTE INFECTIONS IN VERTEBRATES

... pertussis observed in countries with long and efficient diphtheria and pertussis antitoxoid vaccination programs (Schneerson et al. ... A toxoid vaccine for pertussis as well as diphtheria? Lessons to be ...

NBII National Biological Information Infrastructure

162
Changes of the Swedish Bordetella pertussis population in incidence peaks during an acellular pertussis vaccine period between 1997 and 2004.
2007-04-01

In a surveillance programme undertaken from 1997 through 2004, Bordetella pertussis isolates and clinical information were collected after introduction of acellular pertussis vaccines (Pa) in 1996. Changes in the B. pertussis population were studied in three incidence peaks: 1999-2000, 2002 and ...

PubMed

163
ADP-ribosylation activity in pertussis vaccines and its relationship to the in vivo histamine-sensitisation test.
2007-01-19

Pertussis toxin (PTx) is a major virulence factor produced by Bordetella pertussis. In its detoxified form (PTd), it is an important component of acellular pertussis vaccines although some residual PTx activity may likely be present because of the limitations of the detoxification processes ...

PubMed

164
Licensure of a diphtheria and tetanus toxoids and acellular pertussis adsorbed and inactivated poliovirus vaccine and guidance for use as a booster dose.
2008-10-01

On June 24, 2008, the Food and Drug Administration licensed a combined diphtheria and tetanus toxoids and acellular pertussis adsorbed (DTaP) and inactivated poliovirus (IPV) vaccine, DTaP-IPV (Kinrix, GlaxoSmithKline Biologicals, Rixensart, Belgium). Kinrix is licensed for use as the fifth dose of the DTaP vaccine ...

PubMed

165
Outer membrane vesicles obtained from Bordetella pertussis Tohama expressing the lipid A deacylase PagL as a novel acellular vaccine candidate.
2011-01-04

In an effort to devise a safer and effective pertussis acelullar vaccine, outer membrane vesicles (OMVs) were engineered to decrease their endotoxicity. The pagL gene from Bordetella bronchiseptica, which encodes a lipid A 3-deacylase, was expressed in Bordetella pertussis strain Tohama I. The resulting OMVs, designated OMVs(BpPagL), ...

PubMed

166
Immunogenicity study of a combined diphtheria, tetanus, acellular pertussis, inactivated poliomyelitis vaccine used to reconstitute a freeze-dried Haemophilus influenzae type b vaccine (DTaP-IPV//PRP-T) administered simultaneously with a hepatitis B vaccine at two, three and four months of life.
1999-12-10

This study was designed to assess the immunogenicity of a vaccine combining diphtheria and tetanus toxoids, acellular pertussis vaccine, and inactivated poliovirus vaccine reconstituting Haemophilus influenzae type b polysaccharide conjugated to tetanus protein (DTaP-IPV//PRP-T; Pasteur ...

PubMed

167
Immunogenicity and reactogenicity of HbOC vaccine administered simultaneously with acellular pertussis vaccine (DTaP) into either arms or thighs of infants.

To evaluate the reactogenicity and immunogenicity of a Haemophilus influenzae type b conjugate vaccine (HbOC) and of a tricomponent acellular pertussis vaccine (DTaP) when injected simultaneously into either contralateral arms or into contralateral thighs, 110 infants were enrolled to receive three doses of DTaP at ...

PubMed

168
Pertussis immunization in the global pertussis initiative North American region: recommended strategies and implementation considerations.
2005-05-01

In North America, children currently receive 5 doses of a combined diphtheria-tetanus-acellular pertussis vaccine between the ages of 2 months and 6 years. Although this schedule has reduced the incidence of childhood pertussis, it has not led to the development of herd immunity in the total population, largely ...

PubMed

169
Antibody responses to defined regions of the Bordetella pertussis virulence factor pertactin.
2008-01-01

Although vaccines against Bordetella pertussis, the causative agent of whooping cough, have been in use for over 50 y, the disease has remained endemic and is still a public health problem in many countries. It has been shown that antibody titres against pertactin, which is 1 of the exposed virulence factors of pertussis, correlate ...

PubMed

170
Pertussis disease in new mothers: effect on young infants and strategies for prevention.
2009-02-01

Pertussis, or whooping cough, is a major public health problem in the United States, with the incidence of disease and its associated complications having significantly increased in the adolescent and adult populations. These populations serve as the major transmission source of the disease to young infants, a group that is at the highest risk of severe morbidity and mortality ...

PubMed

171
Immunogenicity and reactogenicity of diphtheria-tetanus-acellular pertussis-hepatitis B-inactivated poliovirus and Haemophilus influenzae type B.
2011-05-01

Immunogenicity and reactogenicity of primary vaccination with combined diphtheria-tetanus-acellular pertussis-hepatitis B-inactivated poliovirus (DTPa-HBV-IPV) vaccine when co-administered with Haemophilus influenzae (Hib) conjugate vaccine were assessed in 60 healthy infants. Infants received ...

PubMed

172
Immunogenicity and Safety of Human Papillomavirus-16/18 AS04-adjuvanted Vaccine Coadministered With Tetanus Toxoid, Reduced Diphtheria Toxoid, and Acellular Pertussis Vaccine and/or Meningococcal Conjugate Vaccine to Healthy Girls 11 to 18 Years of Age: Results From a Randomized Open Trial.
2011-08-01

BACKGROUND:: A combined immunization strategy for administration of human papillomavirus (HPV) vaccine with other routine vaccines may lead to better compliance. Reactions and immunologic interference with concomitantly administered vaccines are unpredictable, necessitating clinical evaluation. METHODS:: This was a randomized, open ...

PubMed

173
Interfering effect of diphtheria-tetanus-acellular pertussis combined (DTaP) vaccines on the bacterial endotoxin test.
2001-03-01

We evaluated applicability of the endotoxin test to DTaP vaccines. Although no DTaP vaccine batches showed immediate interference with the activating activity of spiked endotoxin on the clotting of Limulus amaebocyte lysate (LAL), a gradually progressing interference depending on the time after spiking was seen for some of the batches. The interfering DTaP ...

PubMed

174
An adolescent-adult formulation tetanus and diptheria toxoids adsorbed combined with acellular pertussis vaccine has comparable immunogenicity but less reactogenicity in children 4-6 years of age than a pediatric formulation acellular pertussis vaccine and diphtheria and tetanus toxoids adsorbed combined with inactivated poliomyelitis vaccine.
2006-10-02

In Canada, the fifth dose of the routine childhood immunization schedule against diphtheria, tetanus, pertussis and polio is given at 4-6 years of age. Up to 30% of children may have significant local reactions (redness, swelling) and this may be related to pertussis and diphtheria antigen content. We sought to determine if a combination product with lower ...

PubMed

175
Interleukin-1 Receptor Signaling Is Required To Overcome the Effects of Pertussis Toxin and for Efficient Infection- or Vaccination-Induced Immunity against Bordetella pertussis?
2011-01-25

Interleukin-1 receptor-deficient (IL-1R?/?) mice are healthy despite being colonized by commensal microbes but are defective in defenses against specific pathogens, suggesting that IL-1R-mediated effects contribute to immune responses against specific pathogenic mechanisms. To better define the role of IL-1R in immunity to respiratory infections, we challenged ...

PubMed Central

176
Pertussis and patient safety: implementing Tdap vaccine recommendations in hospitals.
2010-04-01

BACKGROUND: Despite the availability of pediatric vaccines against pertussis ("whooping cough"), the disease is poorly controlled. Adolescents and adults with waning immunity, especially immediate family members, are responsible for 76%-83% of pertussis transmission to infants. Adolescent/adult tetanus, diphtheria, and ...

PubMed

177
Seroprevalence of Immunoglobulin G antibodies against pertussis toxin among asymptomatic medical students in the west of Iran: a cross sectional study
2009-05-09

BackgroundPertussis is a highly communicable, vaccine-preventable respiratory infection. Immune response against this disease can be induced by infection or vaccination. Protection after childhood vaccination is minimal after ten years. Our aim was to assess pertussis immunity state in a ...

PubMed Central

178
Minor adverse events in a comparative efficacy trial in Germany in infants receiving either the Lederle/Takeda acellular pertussis component DTP (DTaP) vaccine, the Lederle whole-cell component DTP (DTP) or DT vaccine. The Pertussis Vaccine Study Group.
1997-01-01

Minor adverse events were evaluated in a comparative efficacy trial in Germany in infants who received either the Lederle/Takeda acellular pertussis component DTP (DTaP) vaccine, the Lederle whole-cell component DTP (DTP) or DT vaccine. Vaccinees received four doses (at three, four-and-a half, six and 15-18 months ...

PubMed

179
Immunogenicity and safety of a combined diphtheria, tetanus, acellular pertussis, and inactivated poliovirus vaccine (DTaP-IPV) compared to separate administration of standalone DTaP and IPV vaccines: a randomized, controlled study in infants in the Republic of Korea.
2011-01-06

This randomized trial enrolled 442 infants in the Republic of Korea to assess the immunogenicity and safety of a combined diphtheria, tetanus, acellular pertussis, and inactivated poliovirus vaccine (DTaP-IPV; Tetraxim�) for primary vaccination at 2, 4 and 6 months of age compared with DTaP and IPV ...

PubMed

180
Production and characterization of recombinant pertactin, fimbriae 2 and fimbriae 3 from Bordetella pertussis
2009-12-29

BackgroundBordetella pertussis is a causative agent of pertussis or whooping cough in humans. Pertactin (Prn), fimbriae 2 (Fim2) and fimbriae 3 (Fim3) of B. pertussis are important virulence factors and immunogens which have been included in some acellular pertussis ...

PubMed Central

First Page Previous Page 1 2 3 4 5 6 7 8 9 10 Next Page Last Page
 
First Page Previous Page 1 2 3 4 5 6 7 8 9 10 Next Page Last Page
 
181
Kinetics of the Antibody Response to Tetanus-Diphtheria-Acellular Pertussis Vaccine in Women of Childbearing Age and Postpartum Women.
2011-09-26

Background.?Because adolescents and adults act as a primary source of pertussis infection for infants, vaccination of mothers immediately postpartum is a potential strategy to reduce transmission (cocoon strategy). For this to be effective, high levels of antibodies must be achieved rapidly after vaccination. We sought to determine ...

PubMed

182
Tetanus and pertussis vaccination coverage among adults aged ? 18 years --- United States, 1999 and 2008.
2010-10-15

In 2005, the Advisory Committee on Immunization Practices (ACIP) recommended that the newly licensed tetanus, diphtheria, and acellular pertussis (Tdap) vaccine replace a single decennial dose of tetanus diphtheria (Td) vaccine for persons aged 10-64 years. According to these recommendations, Tdap may be used to ...

PubMed

183
Collaborative study for the standardisation of the histamine sensitizing test in mice and the CHO cell-based assay for the residual toxicity testing of acellular pertussis vaccines.
2010-04-01

The European Pharmacopoeia (Ph. Eur.) and the World Health Organisation (WHO) require the performance of extensive quality and safety control testing before the release on the market of vaccine products for human use. Safety testing with regard to residual pertussis toxin (PT) in acellular pertussis combination ...

PubMed

184
Prevention of pertussis, tetanus, and diphtheria among pregnant and postpartum women and their infants recommendations of the Advisory Committee on Immunization Practices (ACIP).
2008-05-30

In 2005, two tetanus toxoid, reduced diphtheria toxoid, and acellular pertussis (Tdap) vaccines were licensed and recommended for use in adults and adolescents in the United States: ADACEL (sanofi pasteur, Swiftwater, Pennsylvania), which is licensed for use in persons aged 11--64 years, and BOOSTRIX (GlaxoSmithKline Biologicals, ...

PubMed

185
IgE sensitization to gelatin: the probable role of gelatin-containing diphtheria-tetanus-acellular pertussis (DTaP) vaccines.
2000-04-01

We recently found that most events of anaphylaxis to live attenuated viral vaccines containing gelatin as a stabilizer might be caused by the gelatin. However, the mechanism that the children were sensitized to gelatin was unclear. In Japan, both diphtheria-tetanus-acellular pertussis (DTaP) vaccines with and ...

PubMed

186
Immunization programs for infants, children, adolescents, and adults: clinical practice guidelines by the Infectious Diseases Society of America.
2009-09-15

Evidence-based guidelines for immunization of infants, children, adolescents, and adults have been prepared by an Expert Panel of the Infectious Diseases Society of America (IDSA). These updated guidelines replace the previous immunization guidelines published in 2002. These guidelines are prepared for health care professionals who care for either immunocompetent or immunocompromised people of all ...

PubMed

187
Changes in genetic diversity of the Bordetella pertussis population in the United Kingdom between 1920 and 2006 reflect vaccination coverage and emergence of a single dominant clonal type.
2009-01-21

Pertussis (whooping cough) is a potentially fatal respiratory disease caused by the bacterium Bordetella pertussis. Despite effective vaccination programs, there has been concern in some developed countries that pertussis cases are on the increase. We characterized 703 clinical B. pertussis ...

PubMed

188
Changes in Genetic Diversity of the Bordetella pertussis Population in the United Kingdom between 1920 and 2006 Reflect Vaccination Coverage and Emergence of a Single Dominant Clonal Type? �
2009-03-21

Pertussis (whooping cough) is a potentially fatal respiratory disease caused by the bacterium Bordetella pertussis. Despite effective vaccination programs, there has been concern in some developed countries that pertussis cases are on the increase. We characterized 703 clinical B. pertussis ...

PubMed Central

189
Additional Recommendations for Use of Tetanus Toxoid, Reduced-Content Diphtheria Toxoid, and Acellular Pertussis Vaccine (Tdap).
2011-09-26

The American Academy of Pediatrics and the Centers for Disease Control and Prevention are amending previous recommendations and making additional recommendations for the use of tetanus toxoid, reduced-content diphtheria toxoid, and acellular pertussis vaccine (Tdap). Review of the results from clinical trials and other studies has ...

PubMed

190
Antibody decay after immunisation of health-care workers with an acellular pertussis vaccine.
2008-09-17

Antibody decay after a single dose of acellular pertussis vaccine containing 25 microg of pertussis toxin (PT), 25 microg of filamentous hemagglutin (FHA), and traces of pertactin (PRN) was monitored in health-care workers. Blood was sampled 4 weeks (n = 246), 1 year (n = 187), 2 years (n = 53), 3 years (n = 134), ...

PubMed

191
Severe adverse events in a comparative efficacy trial in Germany in infants receiving either the Lederle/Takeda acellular pertussis component DTP (DTaP) vaccine, the Lederle whole-cell component DTP (DTP) or DT vaccine. The Pertussis Vaccine Study Group.
1997-01-01

Severe adverse events were evaluated in a comparative efficacy trial in Germany in infants who received either the Lederle/Takeda acellular pertussis component DTP (DTaP) vaccine, the Lederle whole-cell component DTP (DTP) or DT vaccine. Vaccinees received four doses (at three, four-and-a half, six and 15-18 months ...

PubMed

192
Immunization of Teenagers with a Fifth Dose of Reduced DTaP-IPV Induces High Levels of Pertussis Antibodies with a Significant Increase in Opsonophagocytic Activity.
2011-06-15

Waning vaccine-induced immunity against Bordetella pertussis is observed among adolescents and adults. A high incidence of pertussis has been reported in this population, which serves as a reservoir for B. pertussis. A fifth dose of reduced antigen of diphtheria-tetanus-acellular-pertussis and ...

PubMed

193
Immunogenicity of a Heptavalent Conjugate Pneumococcal Vaccine Administered Concurrently with a Combination Diphtheria, Tetanus, Five-Component Acellular Pertussis, Inactivated Polio, and Haemophilus influenzae Type b Vaccine and a Meningococcal Group C Conjugate Vaccine at 2, 3, and 4 Months of Age ?
2010-03-30

The immunogenicities of conjugate pneumococcal vaccines have been demonstrated when they are administered at 2, 3, and 4 months of age. There is a paucity of data on the immunogenicity of this vaccine when it is administered concurrently with other vaccines in the primary immunization schedule of the United Kingdom. We immunized 55 ...

PubMed Central

194
Tolerability and antibody response in adolescents and adults revaccinated with tetanus toxoid, reduced diphtheria toxoid, and acellular pertussis vaccine adsorbed (Tdap) 4-5 years after a previous dose.
2011-07-28

BACKGROUND: Although decennial adult boosters of tetanus and diphtheria toxoids are recommended in Canada and the United States, a second dose of pertussis vaccine is not currently recommended for adults. METHODS: This open label, post-marketing, multicenter study evaluated the tolerability and immunogenicity of a second dose of an adult formulation of ...

PubMed

195
Changes to the varicella and pertussis immunisation schedule in Germany 2009: background, rationale and implementation.
2010-04-22

In July 2009, the German Standing Committee on Vaccination (STIKO) modified its recommendations for varicella and pertussis vaccination, based on newly available data on disease epidemiology, vaccine effectiveness (VE) and safety, and an evaluation of the feasibility of the recommended immunisation strategy. The ...

PubMed

196
Photolabeling of Glu-129 of the S-1 subunit of pertussis toxin with NAD
1989-11-01

UV irradiation was shown to induce efficient transfer of radiolabel from nicotinamide-labeled NAD to a recombinant protein (C180 peptide) containing the catalytic region of the S-1 subunit of pertussis toxin. Incorporation of label from (3H-nicotinamide)NAD was efficient (0.5 to 0.6 mol/mol of protein) relative to incorporation from (32P-adenylate)NAD (0.2 mol/mol of protein). ...

Energy Citations Database

197
Removal of gelatin from live vaccines and DTaP-an ultimate solution for vaccine-related gelatin allergy.
2003-12-01

From the early 1990s infants started to receive acellular pertussis vaccine combined with diphtheria and tetanus toxoids (DTaP) before live vaccines such as measles, rubella, and mumps vaccines, which contained gelatin as a stabilizer. Then, an increasing number of cases of ...

PubMed

198
Immunogenicity of a hexavalent combination vaccine in rhesus monkeys.
2000-11-22

Preclinical immunogenicity studies were conducted in rhesus monkeys to determine whether there is immune interference in the response to one or more components of a hexavalent vaccine (Hexavac) that contains antigens from Haemophilus influenzae (Hib), hepatitis B (HB), diphtheria (D), tetanus (T), acellular pertussis (aP) and ...

PubMed

199
Update: Vaccines for women, adolescence through adulthood.
2009-08-01

Abstract Recommendations for routine vaccination of adolescents and adults are continually evolving; new vaccines are licensed, and ongoing studies lead to updated recommendations for existing vaccines. Although vaccination is important for both sexes, some recent developments are particularly relevant for women ...

PubMed

200
DTaP-IPV/Hib vaccine (Pentacel).
2008-01-01

The combination vaccine diphtheria and tetanus toxoids and acellular pertussis adsorbed, inactivated poliovirus and Haemophilus b conjugate (tetanus toxoid conjugate) vaccine (DTaP-IPV/Hib), which has been exclusively used in Canada for more than 10 years, is the first DTaP-based vaccine ...

PubMed

First Page Previous Page 1 2 3 4 5 6 7 8 9 10 Next Page Last Page